Association of CYP2D microsatellite polymorphism with Lewy body variant of Alzheimer's disease

Neurology

Volumn 50, Issue 6, 1998, Pages 1556-1562

  Tanaka, S ^a   Chen, X ^a   Xia, Y ^a   Kang, D E ^a   Matoh, N ^d   Sundsmo, M ^a   Thomas, R G ^b   Katzman, R ^b   Thal, L J ^a   Trojanowski, J Q ^c   Saitoh, T ^a   Ueda, K ^d   Masliah, E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSATELLITE DNA;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; GENE LOCATION; GENE LOCUS; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; LEWY BODY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0031779185     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.6.1556     Document Type: Article

References (55)

1. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990;40:1-8.
2. Kalra S, Bergeron C, Lang AE. Lewy body disease and dementia. A review. Arch Intern Med 1996;156:487-493.
3. Kosaka K. Diffuse Lewy body disease in Japan. J Neurol 1990; 237:197-204.
4. Gibb WRG, Esiri MM, Lees AJ. Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 1985;110:1131-1153.
5. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119-139.
6. Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993;52:648-654.
7. Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993;52:183-191.
8. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017-1018.
9. Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-1377.
10. 450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 1993;48:166-168.
11. Saitoh T, Xia Y, Chen X, et al. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann Neurol 1995;37:110-112.
12. Sandy MS, Armstrong M, Tanner CM, et al. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology 1996;47:225-230.
13. Diederich N, Hilger C, Goetz CG, et al. Genetic variability of the CYP2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol 1996;40:463-465.
14. Gasser T, Müler-Myhsok B, Supala A, et al. The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:518-520.
15. Rempfer R, Crook R, Houlden H, et al. Parkinson's disease, but not Alzheimer's disease, Lewy body variant associated with mutant alleles at cytochrome P450 gene. Lancet 1994; 344:815. Letter.
16. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989;45:889-904.
17. 450 CYP2D locus. Nature 1990;347:773-776.
18. 1934 → A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 1990;47:994-1001.
19. Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquin-sparteine polymorphism. Clin Pharmacol Ther 1991;50:233-238.
20. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988;85: 5240-5243.
21. Heim MH, Meyer UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992; 14:49-58.
22. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991;48:943-950.
23. Trofatter JA, Gusella JF, Haines JL. Dinucleotide repeat polymorphism at the debrisoquine 4-hydroxylase (CYP2D) locus. Nucl Acids Res 1991;19:2802.
24. Buetow KH, Duggan D, Yang B, et al. A microsatellite-based multipoint index map of human chromosome 22. Genomics 1993;18:329-339.
25. Gyapay G, Morissette J, Vignal A, et al. The 1993-94 Généthon human genetic linkage map. Nat Genet 1994;7:246-337.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
27. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-1105.
28. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
29. Mirra SS, Hart MN, Terry RD. Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch Pathol Lab Med 1993;117:132-144.
30. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
31. Schmidt ML, Murray J, Lee VM-Y, Hill WD, Wertkin A, Trojanowski JQ. Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol 1991;139:53-65.
32. Wallace DM. Large- and small-scale phenol extractions. In: Berger SL and Kimmel AR. Methods in enzymology, vol 152: Guide to molecular cloning techniques. Orlando: Academic Press, 1987:33-41.
33. Botstein D, White RL, Skolnick M, Davis RW. Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Genet 1980;32:314-331.
34. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
35. Hansen LA, Samuel W. Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies. Neurology 1997; 48:126-132.
36. Samuel W, Galasko D, Masliah E, Hansen LA. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol 1996;55:44-52.
37. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
38. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
39. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ∈4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
40. Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST. APOE*4-associated Alzheimer's disease risk is modified by α1-antichymotrypsin polymorphism. Nat Genet 1995;10:486-488.
41. Wragg M, Hutton M, Talbot C, et al. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Lancet 1996;347:509-512.
42. Okuizumi K, Onodera O, Namba Y, et al. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat Genet 1995;11:207-209.
43. Kang DE, Saitoh T, Chen X, et al. Genetic association of the low-density lipoprotein receptor related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 1997;49:56-61.
44. Hotamisligil GS, Girmen AS, Fink JS, et al. Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. Mov Disord 1994;9:305-310.
45. Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 1993;33:368-372.
46. Xia Y, de Silva HAR, Rosi BL, et al. Genetic studies in Alzheimer's disease with an NACP/α-synuclein polymorphism. Ann Neurol 1996;40:207-215.
47. Fonne-Pfister R, Bargetzi MJ, Meyer UA. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450buf I, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 1987;148:1144-1150.
48. Collins JE, Cole CG, Smink LJ, et al. A high-density YAC contig map of human chromosome 22. Nature 1995;377:367-379.
49. Wilhelmsen K, Mirel D, Marder K, et al. Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13? Ann Neurol 1997;41:813-817.
50. Galasko D, Saitoh T, Xia Y, et al. The apolipoprotein E allele ∈4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease. Neurology 1994;44:1950-1951.
51. Pickering-Brown SM, Mann DMA, Bourke JP, et al. Apolipoprotein E4 and Alzheimer's disease pathology in Lewy body disease and in other β-amyloid-forming diseases. Lancet 1994; 343:1155. Letter.
52. Harrington CR, Louwagie J, Rossau R, et al. Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease. Am J Pathol 1994;145:1472-1484.
53. St Clair D, Norrman J, Perry R, Yates C, Wilcock G, Brookes A. Apolipoprotein E ∈4 allele frequency in patients with Lewy body dementia, Alzheimer's disease and age-matched controls. Neurosci Lett 1994;176:45-46.
54. Hardy J, Crook R, Prihar G, Roberts G, Raghavan R, Perry R. Senile dementia of the Lewy body type has an apolipoprotein E ∈4 allele frequency intermediate between controls and Alzheimer's disease. Neurosci Lett 1994;182:1-2.
55. Chen X, Xia Y, Alford M, et al. The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. Ann Neurol 1995;38:653-658.